Skip to main content

Breast Cancer

Clinical Trials, Breast Cancer

Sacituzumab Govitecan Moves to Second-Line Therapy for Metastatic Triple-Negative Breast Cancer: Applying the Lessons from Clinical Trials to Clinical Practice

Breast Cancer

A Subanalysis of the Phase 3 MONARCH 3 Study of Abemaciclib as Initial Therapy for HR-Positive, HER2-Negative Advanced Breast Cancer

Breast Cancer

Effectiveness of Alpelisib plus Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR-Positive, HER2-Negative, PIK3CA Mutation–Positive Breast Cancer

Breast Cancer

Updates on Endocrine Therapy for Metastatic Breast Cancer

Breast Cancer

Patient-Reported Outcomes from a Phase 3 Trial in Premenopausal Patients with ER-Positive, HER2-Negative, Lymph Node–Positive Breast Cancer

Breast Cancer

Checkpoint Inhibitor Therapy for Metastatic Triple-Negative Breast Cancer

Breast Cancer

Emerging Immunotherapy Combination Strategies for Breast Cancer: Dual Immune Checkpoint Modulation, Antibody–Drug Conjugates, and Bispecific Antibodies

Breast Cancer

Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: An Overview of Clinical Management and Potential Toxicities

Breast Cancer

SASCIA Phase 3 Trial Evaluating Sacituzumab Govitecan in Patients with Primary HER2-Negative Breast Cancer with High Relapse Risk

Breast Cancer

Trastuzumab Deruxtecan Granted Breakthrough Therapy Designation in United States for Patients with HER2-Positive Metastatic Breast Cancer Treated with ≥1 Previous Anti-HER2–Based Regimens

1
2
3
4
5

Page 2 of 11
Results 11 - 20 of 101